WO2011093814A3 - A pharmaceutical combination comprising formoterol and ciclesonide - Google Patents

A pharmaceutical combination comprising formoterol and ciclesonide Download PDF

Info

Publication number
WO2011093814A3
WO2011093814A3 PCT/TR2011/000016 TR2011000016W WO2011093814A3 WO 2011093814 A3 WO2011093814 A3 WO 2011093814A3 TR 2011000016 W TR2011000016 W TR 2011000016W WO 2011093814 A3 WO2011093814 A3 WO 2011093814A3
Authority
WO
WIPO (PCT)
Prior art keywords
ciclesonide
formoterol
pharmaceutical combination
pharmaceutical compositions
capsule
Prior art date
Application number
PCT/TR2011/000016
Other languages
French (fr)
Other versions
WO2011093814A2 (en
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2010/00683A external-priority patent/TR201000683A2/en
Priority claimed from TR2010/00726A external-priority patent/TR201000726A2/en
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2011093814A2 publication Critical patent/WO2011093814A2/en
Publication of WO2011093814A3 publication Critical patent/WO2011093814A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to pharmaceutical compositions in dry powder form comprising formoterol and ciclesonide and/or their pharmaceutically acceptable derivatives as active agents, and capsule and blister forms containing these pharmaceutical compositions so as to be used in treatment of respiratory tract diseases.
PCT/TR2011/000016 2010-01-29 2011-01-28 A pharmaceutical combination comprising formoterol and ciclesonide WO2011093814A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TR2010/00683 2010-01-29
TR2010/00683A TR201000683A2 (en) 2010-01-29 2010-01-29 Pharmaceutical compositions comprising formoterol and ciclesonide.
TR2010/00726A TR201000726A2 (en) 2010-02-02 2010-02-02 Blister forms containing formoterol and ciclesonite
TR2010/00726 2010-02-02

Publications (2)

Publication Number Publication Date
WO2011093814A2 WO2011093814A2 (en) 2011-08-04
WO2011093814A3 true WO2011093814A3 (en) 2012-03-01

Family

ID=43928919

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000016 WO2011093814A2 (en) 2010-01-29 2011-01-28 A pharmaceutical combination comprising formoterol and ciclesonide

Country Status (1)

Country Link
WO (1) WO2011093814A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013109212A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising ciclesonide
EP2804584A1 (en) * 2012-01-16 2014-11-26 Mahmut Bilgic Dry powder formulations comprising carmoterol and ciclesonide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019985A1 (en) * 2002-08-29 2004-03-11 Cipla Ltd Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
WO2004052374A1 (en) * 2002-12-12 2004-06-24 Altana Pharma Ag Combination medicament
EP1626913B1 (en) * 2003-05-28 2010-02-10 Nycomed GmbH Use of ciclesonide for maintaining fine particle fraction of formoterol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
GR1001529B (en) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Process for the obtainment of a new pregna-1,4-diene-3,20-dione -16-17-acetal-21 esters
TR200803523A1 (en) 2008-05-16 2009-12-21 Bi̇lgi̇ç Mahmut Assembly with ribbon packaging
TR200803522A1 (en) 2008-05-16 2009-12-21 Bi̇lgi̇ç Mahmut Easy to use inhalation device.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019985A1 (en) * 2002-08-29 2004-03-11 Cipla Ltd Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
WO2004052374A1 (en) * 2002-12-12 2004-06-24 Altana Pharma Ag Combination medicament
EP1626913B1 (en) * 2003-05-28 2010-02-10 Nycomed GmbH Use of ciclesonide for maintaining fine particle fraction of formoterol

Also Published As

Publication number Publication date
WO2011093814A2 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
IL223783B (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
WO2012016889A3 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
IL213019A (en) 1-aza-3-heteroaryl-azulene derivatives, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
IL223795A (en) Tetrahydro-pyrido-pyrimidine derivatives, process for their preparation, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments
IL206952A (en) Aminodihydrothiazine derivatives, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
JP2010132695A5 (en)
IL216741A (en) 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating diseases
TR201000680A2 (en) Pharmaceutical compositions containing tiotropium, formoterol and budesonide
IL217036A (en) Acetylsalicylic acid addition salt, uses thereof in the preparation of medicaments, pharmaceutical compositions comprising the same and a combination medicinal product comprising such acid addition salt
WO2013183062A3 (en) Palatable formulations of ibuprofen
IL232764A (en) Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments for the treatment of alzheimer's disease
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
NZ605469A (en) Nalbuphine-based formulations and uses thereof
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
WO2011093818A3 (en) Pharmaceutical compositions comprising salmeterol and fluticasone
TR201000733A2 (en) Pharmaceutical compositions comprising fluticasone, tiotropium and sodium chromoglycate.
IL213671A (en) Pharmaceutical compositions comprising aleglitazar, process for their manufacture and use thereof in the preparation of medicaments
WO2011101734A3 (en) Taste-masked powder for suspension compositions of methylprednisolone
IL217519A (en) Tazarotene derivatives, pharmaceutical compositions comprising them and use thereof for the manufacture of medicaments for the treatment of skin disorders
WO2011093811A3 (en) Pharmaceutical preparations comprising formoterol and fluticasone
PL2640364T3 (en) Pharmaceutical composition comprising bicarbonate salt, and use thereof as a medicament in the treatment and/or prevention of urinary lithiasis and related diseases
WO2011093814A3 (en) A pharmaceutical combination comprising formoterol and ciclesonide
EP2583966A4 (en) Tricarbonyl technetium-99m or rhenium-188 label ring rgd derivative, a preparation method thereof, and a pharmaceutical composition containing the derivative as an active ingredient for use in the diagnosis or treatment of angiogenesis-related diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11706648

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11706648

Country of ref document: EP

Kind code of ref document: A2